Passage Bio Inc (NASDAQ: PASG ) is one of the best gene therapy stocks to buy in 2026 . While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months.
On April 20, Passage Bio said it was reviewing its strategic alternatives to maximize shareholder value. It has tapped Wedbush PacGrow as a financial advisor to help with this task.
Passage Bio's lead product candidate is PBFT02. The company is developing PBFT02 as a potential treatment for frontotemporal dementia. A Phase 1/2 trial of this gene therapy is ongoing.
Interim data from that trial suggested that PBFT02 may slow disease progression in patients with frontotemporal dementia. The management cited improvements in both brain atrophy and plasma neurofilament levels, and noted that these two are well-established biomarkers of disease progression.
However, when the company met with the FDA, the regulator indicated that it would require a randomized controlled trial for registrational purposes. Passage Bio's management said that in light of this outcome as well as taking into account logistical and financial challenges, they are viewing the next steps for the PBFT02 program as and the company.
Pennsylvania-based Passage Bio Inc (NASDAQ:PASG) is a genetic medicines company. Passage Bio is developing gene therapies for central nervous system disorders. Its programs target hard-to-treat, devastating diseases.
While we acknowledge the potential of PASG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 8 Best Middle East and Africa Stocks to Buy According to Hedge Funds and 10 Undervalued Aerospace and Defense Stocks to Buy .
Disclosure: None. Follow Insider Monkey on Google News .
